Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > Less than two years after stopping obesity drugs, weight and health issues return, study finds
    Finance

    Less than two years after stopping obesity drugs, weight and health issues return, study finds

    Published by Global Banking & Finance Review®

    Posted on January 8, 2026

    2 min read

    Last updated: January 20, 2026

    Less than two years after stopping obesity drugs, weight and health issues return, study finds - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:research

    Quick Summary

    Obesity drugs' benefits on weight and health issues fade within two years, with patients regaining weight and health risks returning.

    Study Finds Obesity Drugs' Benefits Fade in Less Than Two Years

    By Nancy Lapid

    Jan 7 (Reuters) - When patients stop taking weight-loss medications, the beneficial effects of the drugs on weight and other health issues disappear within two years, a large analysis of earlier research has found.

    Reviewing data on 9,341 obese or overweight patients treated in 37 studies with any of 18 different weight-loss medications, researchers found they regained on average nearly one pound (0.4 kg) per month after stopping the drugs, and were projected to return to pre-treatment weight by 1.7 years. 

    Heart health risk factors, such as blood pressure and cholesterol levels, that benefited from the drugs were projected to return to pre-treatment levels within 1.4 years after stopping the medications, on average, according to a report of the study in The BMJ.

    Roughly half of the patients had taken GLP-1 medications, including 1,776 who received the newer, more effective drugs semaglutide, sold as Ozempic and Wegovy by Novo Nordisk, and tirzepatide, sold as Mounjaro and Zepbound by Eli Lilly. 

    The weight regain rate was faster with semaglutide and tirzepatide, averaging nearly 1.8 pounds (0.8 kg) per month.

    “But because people on semaglutide or tirzepatide lose more weight in the first place, they all end up returning to baseline at approximately the same time,” said study senior researcher Dimitrios Koutoukidis of Oxford University. That was roughly 1.5 years with these new drugs versus 1.7 years after stopping any of the drugs.

    Regardless of how much weight was lost, monthly weight regain was faster after weight-loss drugs than after behavioral weight management programs, the researchers also found. 

    The retrospective study could not determine whether some patients were more likely than others to keep off the weight.

    “Understanding who does well and who does not is a bit of a ‘holy grail’ question in weight-loss research, but nobody has the answer to that yet,” Koutoukidis said. 

    (Reporting by Nancy Lapid; Editing by Bill Berkrot)

    Key Takeaways

    • •Weight-loss drug benefits fade within two years.
    • •Patients regain weight after stopping medications.
    • •Heart health risks return post-treatment.
    • •GLP-1 drugs show faster weight regain.
    • •Study highlights need for long-term solutions.

    Frequently Asked Questions about Less than two years after stopping obesity drugs, weight and health issues return, study finds

    1What is the main topic?

    The article discusses the fading effects of obesity drugs on weight and health issues within two years after stopping treatment.

    2What are GLP-1 medications?

    GLP-1 medications are a class of drugs used for weight loss, including semaglutide and tirzepatide, which show faster weight regain.

    3How quickly do patients regain weight?

    Patients regain nearly one pound per month after stopping weight-loss drugs, returning to pre-treatment weight in about 1.7 years.

    More from Finance

    Explore more articles in the Finance category

    Image for Japan's Takaichi aims for blizzard of votes in rare winter election
    Japan's Takaichi aims for blizzard of votes in rare winter election
    Image for Rugby-Ford shines as England overwhelm dismal Wales
    Rugby-Ford shines as England overwhelm dismal Wales
    Image for Greenland foreign minister says US talks are positive but the outcome remains uncertain
    Greenland foreign minister says US talks are positive but the outcome remains uncertain
    Image for Hungary's opposition Tisza promises wealth tax, euro adoption in election programme
    Hungary's opposition Tisza promises wealth tax, euro adoption in election programme
    Image for Farmers report 'catastrophic damage to crops as Storm Marta hits Spain and Portugal
    Farmers report 'catastrophic damage to crops as Storm Marta hits Spain and Portugal
    Image for If US attacks, Iran says it will strike US bases in the region
    If US attacks, Iran says it will strike US bases in the region
    Image for Olympics-Biathlon-Winter Games bring tourism boost to biathlon hotbed of northern Italy
    Olympics-Biathlon-Winter Games bring tourism boost to biathlon hotbed of northern Italy
    Image for Analysis-Bitcoin loses Trump-era gains as crypto market volatility signals uncertainty
    Analysis-Bitcoin loses Trump-era gains as crypto market volatility signals uncertainty
    Image for NatWest closes in on $3.4 billion takeover of wealth manager Evelyn, Sky News reports
    NatWest closes in on $3.4 billion takeover of wealth manager Evelyn, Sky News reports
    Image for Stellantis-backed ACC drops plans for Italian, German gigafactories, union says
    Stellantis-backed ACC drops plans for Italian, German gigafactories, union says
    Image for US pushes Russia and Ukraine to end war by summer, Zelenskiy says
    US pushes Russia and Ukraine to end war by summer, Zelenskiy says
    Image for Russia launches massive attack on Ukraine's energy system, Zelenskiy says
    Russia launches massive attack on Ukraine's energy system, Zelenskiy says
    View All Finance Posts
    Previous Finance PostWorld Economic Forum survey shows doing business got tougher in 2025
    Next Finance PostExplainer-Why are French farmers driving their tractors into Paris?